Genedx Holdings Corp. - Class A (WGS) closed at $69.06 on October 30, 2026, down 2.8% from the previous close, on volume of 708,218 shares (30-day average 837,681).
Data as of October 30, 2026.
Did GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Tue, 27-Oct 3:28 PM ET)
GeneDx (WGS) Sets Nov. 9 Q3 2026 Results Date, Putting Focus on the 4:30 p.m. ET Call
Market Chameleon (Mon, 26-Oct 4:55 AM ET)
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
Business Wire (Fri, 23-Oct 4:05 PM ET)
Business Wire (Tue, 20-Oct 8:30 AM ET)
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
Business Wire (Mon, 19-Oct 4:05 PM ET)
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
Business Wire (Wed, 7-Oct 8:30 AM ET)
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
Business Wire (Fri, 2-Oct 8:30 AM ET)
Business Wire (Wed, 9-Sep 8:30 AM ET)
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
Business Wire (Tue, 1-Sep 6:55 AM ET)
Business Wire (Mon, 24-Aug 8:30 AM ET)
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Genedx Holdings Corp. - Class A trades on the NASDAQ stock market under the symbol WGS.
As of October 30, 2026, WGS stock price declined to $69.06 with 708,218 million shares trading.
WGS has a beta of 0.74, meaning it tends to be less sensitive to market movements. WGS has a correlation of 0.01 to the broad based SPY ETF.
WGS has a market cap of $2.05 billion. This is considered a Mid Cap stock.
Last quarter Genedx Holdings Corp. - Class A reported $114 million in Revenue and $.01 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.20.
In the last 3 years, WGS traded as high as $170.87 and as low as $1.16.
The top ETF exchange traded funds that WGS belongs to (by Net Assets): ARKK, ARKE, VTI, ARKG, IWM.
WGS has underperformed the market in the last year with a return of -47.6%, while SPY returned +11.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in WGS shares. However, WGS has outperformed the market in the last 3 month and 2 week periods, returning +8.4% and -1.7%, while SPY returned +3.9% and -2.1%, respectively. This indicates WGS has been having a stronger performance recently.
WGS support price is $67.17 and resistance is $74.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WGS shares will trade within this expected range on the day.
